[Federal Register Volume 80, Number 67 (Wednesday, April 8, 2015)]
[Notices]
[Pages 18928-18935]
[FR Doc No: 2015-08053]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2015-0057]

Qualification of Drivers; Exemption Applications; Diabetes
Mellitus

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), Department
of Transportation.

ACTION: Notice of applications for exemptions request for comments.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces receipt of applications from 49 individuals
for exemption from the prohibition against persons with insulin-treated
diabetes mellitus (ITDM) operating commercial motor vehicles (CMVs) in
interstate commerce. If granted, the exemptions would enable these
individuals with ITDM to operate CMVs in interstate commerce.

DATES: Comments must be received on or before May 8, 2015.

ADDRESSES: You may submit comments bearing the Federal Docket
Management System (FDMS) Docket No. FMCSA-2015-0057 using any of the
following methods:
     Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the on-line instructions for submitting
comments.
     Mail: Docket Management Facility; U.S. Department of
Transportation, 1200 New Jersey Avenue SE., West Building Ground Floor,
Room W12-140, Washington, DC 20590-0001.
     Hand Delivery: West Building Ground Floor, Room W12-140,
1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal Holidays.
     Fax: 1-202-493-2251.
    Instructions: Each submission must include the Agency name and the
docket numbers for this notice. Note that all comments received will be
posted without change to http://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading below
for further information.
    Docket: For access to the docket to read background documents or
comments, go to http://www.regulations.gov at any time or Room W12-140
on the ground level of the West Building, 1200 New Jersey Avenue SE.,
Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays. The Federal Docket Management System (FDMS) is
available 24 hours each day, 365 days each year. If you want
acknowledgment that we received your comments, please include a self-
addressed, stamped envelope or postcard or print the acknowledgement
page that appears after submitting comments on-line.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to www.regulations.gov, as described in the
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.

FOR FURTHER INFORMATION CONTACT: Charles A. Horan, III, Director,
Carrier, Driver and Vehicle Safety Standards,<PHONE_NUMBER>,
<EMAIL_ADDRESS>FMCSA, Department of Transportation, 1200 New
Jersey Avenue SE., Room W64-224, Washington, DC 20590-0001. Office
hours are from 8:30 a.m. to 5 p.m., Monday through Friday, except
Federal holidays.

SUPPLEMENTARY INFORMATION:

I. Background

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption
from the Federal Motor Carrier Safety Regulations for a 2-year period
if it finds ``such exemption would likely achieve a level of safety
that is equivalent to or greater than the level that would be achieved
absent such exemption.'' The statute also allows the Agency to renew
exemptions at the end of the 2-year period. The 49 individuals listed
in this notice have recently requested such an exemption from the
diabetes prohibition in 49 CFR 391.41(b)(3), which applies to drivers
of CMVs in interstate commerce. Accordingly, the Agency will evaluate
the qualifications of each applicant to determine whether granting the
exemption will achieve the required level of safety mandated by
statute.

II. Qualifications of Applicants

Christopher R. Alba

    Mr. Alba, 35, has had ITDM since 2014. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Alba understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Alba meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2015 and certified that he does not have diabetic retinopathy. He
holds a Class B CDL from Colorado.

Lloyd T. Beverly

    Mr. Beverly, 65, has had ITDM since 2014. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Beverly understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Beverly meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2014 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Virginia.

James R. Bledsoe

    Mr. Bledsoe, 65, has had ITDM since 2001. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Bledsoe understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Bledsoe meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Florida.

Sammy W. Bowlin

    Mr. Bowlin, 58, has had ITDM since 2012. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Bowlin understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Bowlin meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Kansas.

Durwin A. Brannon

    Mr. Brannon, 59, has had ITDM since 2009. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Brannon understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Brannon meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2014 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from North Carolina.

Larry J. Carril

    Mr. Carril, 64, has had ITDM since 2014. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Carril understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Carril meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Illinois.

Jimmy E. Cole

    Mr. Cole, 66, has had ITDM since 2012. His endocrinologist examined
him in 2014 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Cole understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Cole meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2015 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Tennessee.

Richard S. Collins

    Mr. Collins, 45, has had ITDM since 2013. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the

past 12 months and no recurrent (2 or more) severe hypoglycemic
episodes in the last 5 years. His endocrinologist certifies that Mr.
Collins understands diabetes management and monitoring, has stable
control of his diabetes using insulin, and is able to drive a CMV
safely. Mr. Collins meets the requirements of the vision standard at 49
CFR 391.41(b)(10). His optometrist examined him in 2015 and certified
that he does not have diabetic retinopathy. He holds an operator's
license from Iowa.

Robert S. Colosimo

    Mr. Colosimo, 64, has had ITDM since 2011. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Colosimo understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Colosimo meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from North Dakota.

Joel F. Cook

    Mr. Cook, 40, has had ITDM since 1990. His endocrinologist examined
him in 2014 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Cook understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Cook meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2014 and certified that he has stable nonproliferative diabetic
retinopathy. He holds a Class B CDL from New York.

James N. Coombs

    Mr. Coombs, 52, has had ITDM since 2015. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Coombs understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Coombs meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from New Jersey.

David A. Daniels

    Mr. Daniels, 60, has had ITDM since 2015. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Daniels understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Daniels meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Maine.

Mark J. Dias

    Mr. Dias, 47, has had ITDM since 2012. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Dias understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Dias meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2015 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Massachusetts.

William A. Emerick

    Mr. Emerick, 74, has had ITDM since 2011. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Emerick understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Emerick meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Massachusetts.

Brian A. Foss

    Mr. Foss, 38, has had ITDM since 1982. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Foss understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Foss meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2014 and certified that he does not have diabetic retinopathy.
He holds an operator's license from Wyoming.

William A. H. Gardner

    Mr. Gardner, 44, has had ITDM since 1981. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Gardner understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Gardner meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from California.

Gary R. Gill

    Mr. Gill, 61, has had ITDM since 2014. His endocrinologist examined
him

in 2015 and certified that he has had no severe hypoglycemic reactions
resulting in loss of consciousness, requiring the assistance of another
person, or resulting in impaired cognitive function that occurred
without warning in the past 12 months and no recurrent (2 or more)
severe hypoglycemic episodes in the last 5 years. His endocrinologist
certifies that Mr. Gill understands diabetes management and monitoring,
has stable control of his diabetes using insulin, and is able to drive
a CMV safely. Mr. Gill meets the requirements of the vision standard at
49 CFR 391.41(b)(10). His optometrist examined him in 2014 and
certified that he does not have diabetic retinopathy. He holds a Class
A CDL from Pennsylvania.

Steven M. Gilmour

    Mr. Gilmour, 55, has had ITDM since 2014. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Gilmour understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Gilmour meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class B CDL from Massachusetts.

Ismael Gonzalez

    Mr. Gonzalez, 60, has had ITDM since 2013. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Gonzalez understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Gonzalez meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Indiana.

Arnold P. Griffith, Jr.

    Mr. Griffith, 71, has had ITDM since 2012. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Griffith understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Griffith meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2014 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Iowa.

Charles A. Gudaitis

    Mr. Gudaitis, 50, has had ITDM since 1994. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Gudaitis understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Gudaitis meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2014 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Pennsylvania.

Scott D. Hanlon

    Mr. Hanlon, 58, has had ITDM since 2013. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Hanlon understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Hanlon meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from New
York.

Cory A. Harker

    Mr. Harker, 24, has had ITDM since 2000. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Harker understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Harker meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class C CDL from Florida.

Stanley A. Head

    Mr. Head, 63, has had ITDM since 2013. His endocrinologist examined
him in 2014 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Head understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Head meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2014 and certified that he does not have diabetic retinopathy.
He holds a Class B CDL from Georgia.

David W. Henderson

    Mr. Henderson, 58, has had ITDM since 2012. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Henderson understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Henderson meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist

examined him in 2014 and certified that he does not have diabetic
retinopathy. He holds a Class A CDL from North Carolina.

Clark D. Holdeman

    Mr. Holdeman, 32, has had ITDM since 2007. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Holdeman understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Holdeman meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Texas.

William E. Holt

    Mr. Holt, 58, has had ITDM since 2012. His endocrinologist examined
him in 2014 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Holt understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Holt meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2014 and certified that he does not have diabetic retinopathy.
He holds a Class B CDL from Texas.

David A. Holwegner

    Mr. Holwegner, 57, has had ITDM since 2014. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Holwegner understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Holwegner meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Washington.

Alan D. Jacobs

    Mr. Jacobs, 65, has had ITDM since 2000. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Jacobs understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Jacobs meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from Oregon.

Conrad J. Janik

    Mr. Janik, 61, has had ITDM since 1973. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Janik understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Janik meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2014 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from New York.

David F. Kenny

    Mr. Kenny, 52, has had ITDM since 2014. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Kenny understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Kenny meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he does not
have diabetic retinopathy. He holds a Class A CDL from New York.

George W. Key, Jr.

    Mr. Key, 58, has had ITDM since 2012. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Key understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Key meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2015 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Alabama.

Michael O. Lancial

    Mr. Lancial, 56, has had ITDM since 2006. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Lancial understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Lancial meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a chauffeur's license
from Michigan.

Frank A. Mowers

    Mr. Mowers, 81, has had ITDM since 2011. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in

the last 5 years. His endocrinologist certifies that Mr. Mowers
understands diabetes management and monitoring, has stable control of
his diabetes using insulin, and is able to drive a CMV safely. Mr.
Mowers meets the requirements of the vision standard at 49 CFR
391.41(b)(10). His ophthalmologist examined him in 2015 and certified
that he does not have diabetic retinopathy. He holds a Class B CDL from
Illinois.

Charles H. Nichols

    Mr. Nichols, 51, has had ITDM since 2008. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Nichols understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Nichols meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2014 and certified that he does not
have diabetic retinopathy. He holds a chauffeur's license from
Michigan.

Marvin R. Nunn

    Mr. Nunn, 57, has had ITDM since 2010. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Nunn understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Nunn meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2015 and certified that he has stable nonproliferative diabetic
retinopathy. He holds an operator's license from Oregon.

Terry C. Rose

    Mr. Rose, 70, has had ITDM since 2014. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Rose understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Rose meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2015 and certified that he does not have diabetic retinopathy.
He holds an operator's license from North Carolina.

Robert L. Rush, Jr.

    Mr. Rush, 42, has had ITDM since 2014. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Rush understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Rush meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2015 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Pennsylvania.

Derek J. Scougal

    Mr. Scougal, 35, has had ITDM since 2009. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Scougal understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Scougal meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class A CDL from
Virginia.

Roy Silva

    Mr. Silva, 59, has had ITDM since 2000. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Silva understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Silva meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2014 and certified that he has stable
nonproliferative diabetic retinopathy. He holds a Class B CDL from
Illinois.

James L. Skinner

    Mr. Skinner, 46, has had ITDM since 1975. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Skinner understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Skinner meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2014 and certified that he has stable
proliferative diabetic retinopathy. He holds a Class A CDL from Iowa.

Robert L. Terry

    Mr. Terry, 53, has had ITDM since 2010. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Terry understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Terry meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2014 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from Tennessee.

Rafael Torres, Jr.

    Mr. Torres, 54, has had ITDM since 2014. His endocrinologist
examined him

in 2015 and certified that he has had no severe hypoglycemic reactions
resulting in loss of consciousness, requiring the assistance of another
person, or resulting in impaired cognitive function that occurred
without warning in the past 12 months and no recurrent (2 or more)
severe hypoglycemic episodes in the last 5 years. His endocrinologist
certifies that Mr. Torres understands diabetes management and
monitoring, has stable control of his diabetes using insulin, and is
able to drive a CMV safely. Mr. Torres meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His optometrist examined him
in 2014 and certified that he does not have diabetic retinopathy. He
holds a Class A CDL from Florida.

Matthew C. Vaillancourt

    Mr. Vaillancourt, 27, has had ITDM since 2012. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Vaillancourt understands
diabetes management and monitoring, has stable control of his diabetes
using insulin, and is able to drive a CMV safely. Mr. Vaillancourt
meets the requirements of the vision standard at 49 CFR 391.41(b)(10).
His optometrist examined him in 2014 and certified that he does not
have diabetic retinopathy. He holds an operator's license from
Massachusetts.

Joseph E. Weitzel

    Mr. Weitzel, 55, has had ITDM since 2005. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Weitzel understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Weitzel meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
ophthalmologist examined him in 2015 and certified that he does not
have diabetic retinopathy. He holds a Class B CDL from Pennsylvania.

Ashley M. Winkels

    Ms. Winkels, 30, has had ITDM since 2014. Her endocrinologist
examined her in 2014 and certified that she has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
Her endocrinologist certifies that Ms. Winkels understands diabetes
management and monitoring, has stable control of her diabetes using
insulin, and is able to drive a CMV safely. Ms. Winkels meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). Her
optometrist examined her in 2015 and certified that she does not have
diabetic retinopathy. She holds an operator's license from Minnesota.

Steven L. Wolvers

    Mr. Wolvers, 56, has had ITDM since 1995. His endocrinologist
examined him in 2015 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Wolvers understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Wolvers meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds an operator's license from Iowa.

David W. Wood

    Mr. Wood, 75, has had ITDM since 2012. His endocrinologist examined
him in 2015 and certified that he has had no severe hypoglycemic
reactions resulting in loss of consciousness, requiring the assistance
of another person, or resulting in impaired cognitive function that
occurred without warning in the past 12 months and no recurrent (2 or
more) severe hypoglycemic episodes in the last 5 years. His
endocrinologist certifies that Mr. Wood understands diabetes management
and monitoring, has stable control of his diabetes using insulin, and
is able to drive a CMV safely. Mr. Wood meets the requirements of the
vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined
him in 2014 and certified that he does not have diabetic retinopathy.
He holds a Class A CDL from Idaho.

Donald E. Zimmerman

    Mr. Zimmerman, 70, has had ITDM since 2013. His endocrinologist
examined him in 2014 and certified that he has had no severe
hypoglycemic reactions resulting in loss of consciousness, requiring
the assistance of another person, or resulting in impaired cognitive
function that occurred without warning in the past 12 months and no
recurrent (2 or more) severe hypoglycemic episodes in the last 5 years.
His endocrinologist certifies that Mr. Zimmerman understands diabetes
management and monitoring, has stable control of his diabetes using
insulin, and is able to drive a CMV safely. Mr. Zimmerman meets the
requirements of the vision standard at 49 CFR 391.41(b)(10). His
optometrist examined him in 2015 and certified that he does not have
diabetic retinopathy. He holds a Class A CDL from North Carolina.

III. Request for Comments

    In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests
public comment from all interested persons on the exemption petitions
described in this notice. We will consider all comments received before
the close of business on the closing date indicated in the date section
of the notice.
    FMCSA notes that section 4129 of the Safe, Accountable, Flexible
and Efficient Transportation Equity Act: A Legacy for Users requires
the Secretary to revise its diabetes exemption program established on
September 3, 2003 (68 FR 52441) \1\. The revision must provide for
individual assessment of drivers with diabetes mellitus, and be
consistent with the criteria described in section 4018 of the
Transportation Equity Act for the 21st Century (49 U.S.C. 31305).
---------------------------------------------------------------------------

    \1\ Section 4129(a) refers to the 2003 notice as a ``final
rule.'' However, the 2003 notice did not issue a ``final rule'' but
did establish the procedures and standards for issuing exemptions
for drivers with ITDM.
---------------------------------------------------------------------------

    Section 4129 requires: (1) Elimination of the requirement for 3
years of experience operating CMVs while being treated with insulin;
and (2) establishment of a specified minimum period of insulin use to
demonstrate stable control of diabetes before being allowed to operate
a CMV.
    In response to section 4129, FMCSA made immediate revisions to the
diabetes exemption program established by the September 3, 2003 notice.
FMCSA discontinued use of the 3-year driving experience and fulfilled
the

requirements of section 4129 while continuing to ensure that operation
of CMVs by drivers with ITDM will achieve the requisite level of safety
required of all exemptions granted under 49 U.S.C. 31136(e).
    Section 4129(d) also directed FMCSA to ensure that drivers of CMVs
with ITDM are not held to a higher standard than other drivers, with
the exception of limited operating, monitoring and medical requirements
that are deemed medically necessary.
    The FMCSA concluded that all of the operating, monitoring and
medical requirements set out in the September 3, 2003 notice, except as
modified, were in compliance with section 4129(d). Therefore, all of
the requirements set out in the September 3, 2003 notice, except as
modified by the notice in the Federal Register on November 8, 2005 (70
FR 67777), remain in effect.

IV. Submitting Comments

    You may submit your comments and material online or by fax, mail,
or hand delivery, but please use only one of these means. FMCSA
recommends that you include your name and a mailing address, an email
address, or a phone number in the body of your document so that FMCSA
can contact you if there are questions regarding your submission.
    To submit your comment online, go to http://www.regulations.gov and
in the search box insert the docket number FMCSA-2015-0057 and click
the search button. When the new screen appears, click on the blue
``Comment Now!'' button on the right hand side of the page. On the new
page, enter information required including the specific section of this
document to which each comment applies, and provide a reason for each
suggestion or recommendation. If you submit your comments by mail or
hand delivery, submit them in an unbound format, no larger than 8\1/2\
by 11 inches, suitable for copying and electronic filing. If you submit
comments by mail and would like to know that they reached the facility,
please enclose a stamped, self-addressed postcard or envelope.
    We will consider all comments and material received during the
comment period and may change this proposed rule based on your
comments. FMCSA may issue a final rule at any time after the close of
the comment period.

V. Viewing Comments and Documents

    To view comments, as well as any documents mentioned in this
preamble, To submit your comment online, go to http://www.regulations.gov and in the search box insert the docket number
FMCSA-2015-0057 and click ``Search.'' Next, click ``Open Docket
Folder'' and you will find all documents and comments related to the
proposed rulemaking.

    Issued on: April 2, 2015.
Larry W. Minor,
 Associate Administrator for Policy.
[FR Doc. 2015-08053 Filed 4-7-15; 8:45 am]
 BILLING CODE P


[Federal Register Volume 75, Number 240 (Wednesday, December 15, 2010)]
[Notices]
[Pages 78278-78279]
[FR Doc No: 2010-31447]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-63485; File No. SR-CBOE-2010-113]

Self-Regulatory Organizations; Chicago Board Options Exchange,
Incorporated; Notice of Filing and Immediate Effectiveness of Proposed
Rule Change Related to the Extension of the Clearly Erroneous Policy
Pilot Program

December 9, 2010.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(the ``Act''),\1\ and Rule 19b-4 thereunder,\2\ notice is hereby given
that on December 8, 2010, the Chicago Board Options Exchange,
Incorporated (``Exchange'' or ``CBOE'') filed with the Securities and
Exchange Commission (the ``Commission'') the proposed rule change as
described in Items I and II below, which Items have been prepared by
the Exchange. The Exchange has designated the proposal as a ``non-
controversial'' proposed rule change pursuant to Section
19(b)(3)(A)(iii) of the Act \3\ and Rule 19b-4(f)(6) thereunder.\4\ The
Commission is publishing this notice to solicit comments on the
proposed rule change from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ 15 U.S.C. 78s(b)(3)(A)(iii).
    \4\ 17 CFR 240.19b-4(f)(6).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to extend a pilot program pertaining to the
CBOE Stock Exchange (``CBSX''), the CBOE's stock trading facility,
through April 11, 2011. This rule change simply seeks to extend the
pilot. No other changes to the pilot are being proposed. The text of
the proposed rule change is available on the Exchange's Web site http://www.cboe.org/Legal, at the Exchange's Office of the Secretary, at the
Commission's Public Reference Room, and on the Commission's Web site
(www.sec.gov).

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of those statements may be examined at the places specified in
Item IV below. The Exchange has prepared summaries, set forth in
sections A, B, and C below, of the most significant parts of such
statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and the
Statutory Basis for, the Proposed Rule Change

1. Purpose
    Certain amendments to Rule 52.4, Clearly Erroneous Policy, were
approved by the Commission on September 10, 2010 on a pilot basis to
end on December 10, 2010.\5\ The clearly erroneous policy changes were
developed in consultation with other markets and the Commission staff
to provide for uniform treatment: (i) Of clearly erroneous execution
reviews in Multi-Stock Events involving twenty or more securities; and
(ii) in the event transactions occur that result in the issuance of an
individual stock trading

pause by the primary market and subsequent transactions that occur
before the trading pause is in effect on the Exchange. Additional
changes were also made to Rule 52.4 that reduce the ability of the
Exchange to deviate from the objective standards set forth in the Rule.
As the duration of the pilot expires on December 10, 2010, the Exchange
is proposing to extend the effectiveness of the clearly erroneous
policy changes to Rule 52.4 through April 11, 2011.
---------------------------------------------------------------------------

    \5\ Securities Exchange Act Release No. 62886 (September 10,
2010), 75 FR 56613 (September 16, 2010) (SR-CBOE-2010-056).
---------------------------------------------------------------------------

2. Statutory Basis
    Extension of the pilot period will allow the Exchange to continue
to operate the pilot on an uninterrupted basis. Accordingly, CBOE
believes the proposed rule change is consistent with the Act \6\ and
the rules and regulations under the Act applicable to a national
securities exchange and, in particular, the requirements of Section
6(b) of the Act.\7\ Specifically, the Exchange believes the proposed
rule change is consistent with the Section 6(b)(5) \8\ requirements
that the rules of an exchange be designed to promote just and equitable
principles of trade, to prevent fraudulent and manipulative acts and,
in general, to protect investors and the public interest.
---------------------------------------------------------------------------

    \6\ 15 U.S.C. 78a et seq.
    \7\ 15 U.S.C. 78(f)(b).
    \8\ 15 U.S.C. 78(f)(b)(5).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    CBOE does not believe that the proposed rule change will impose any
burden on competition that is not necessary or appropriate in
furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants, or Others

    The Exchange neither solicited nor received comments on the
proposal.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Because the foregoing proposed rule change does not: (i)
Significantly affect the protection of investors or the public
interest; (ii) impose any significant burden on competition; and (iii)
become operative for 30 days from the date on which it was filed, or
such shorter time as the Commission may designate, it has become
effective pursuant to Section 19(b)(3)(A) of the Act \9\ and Rule 19b-
4(f)(6)(iii) thereunder.\10\ The Exchange has asked the Commission to
waive the 30-day operative delay so that the proposal may become
operative immediately upon filing. The Commission believes that waiving
the 30-day operative delay is consistent with the protection of
investors and the public interest because such waiver will allow the
pilot program to continue uninterrupted and help ensure uniformity
among the national securities exchanges and FINRA with respect to the
treatment of clearly erroneous transactions.\11\ Accordingly, the
Commission waives the 30-day operative delay requirement and designates
the proposed rule change as operative upon filing with the Commission.
---------------------------------------------------------------------------

    \9\ 15 U.S.C. 78s(b)(3)(A).
    \10\ 17 CFR 240.19b-4(f)(6)(iii). In addition, Rule 19b-
4(f)(6)(iii) requires that a self-regulatory organization submit to
the Commission written notice of its intent to file the proposed
rule change, along with a brief description and text of the proposed
rule change, at least five business days prior to the filing of the
proposed rule change, or such shorter time as designated by the
Commission. The Commission notes that the Exchange has satisfied
this requirement.
    \11\ For purposes only of waiving the 30-day operative delay,
the Commission has considered the proposed rule's impact on
efficiency, competition, and capital formation. See 15 U.S.C.
78c(f).
---------------------------------------------------------------------------

    At any time within 60 days of the filing of the proposed rule
change, the Commission summarily may temporarily suspend such rule
change if it appears to the Commission that such action is necessary or
appropriate in the public interest, for the protection of investors, or
otherwise in furtherance of the purposes of the Act.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form http://www.sec.gov/rules/sro.shtml; or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-CBOE-2010-113 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-CBOE-2010-113. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site http://www.sec.gov/rules/sro.shtml.
Copies of the submission, all subsequent amendments, all written
statements with respect to the proposed rule change that are filed with
the Commission, and all written communications relating to the proposed
rule change between the Commission and any person, other than those
that may be withheld from the public in accordance with the provisions
of 5 U.S.C. 552, will be available for Web site viewing and printing in
the Commission's Public Reference Room, 100 F Street, NE., Washington,
DC 20549, on official business days between the hours of 10 a.m. and 3
p.m. Copies of such filing also will be available for inspection and
copying at the principal office of the Exchange. All comments received
will be posted without change; the Commission does not edit personal
identifying information from submissions. You should submit only
information that you wish to make publicly available. All submissions
should refer to File Number SR-CBOE-2010-113 and should be submitted on
or before January 5, 2011.

    For the Commission, by the Division of Trading and Markets,
pursuant to delegated authority.\12\
---------------------------------------------------------------------------

    \12\ 17 CFR 200.30-3(a)(12).
---------------------------------------------------------------------------

Florence E. Harmon,
Deputy Secretary.
[FR Doc. 2010-31447 Filed 12-14-10; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register Volume 80, Number 240 (Tuesday, December 15, 2015)]
[Notices]
[Pages 77625-77626]
[FR Doc No: 2015-31465]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL-9940-04-OA]

Notification of Two Teleconferences and a Face-to-Face Meeting of
the Science Advisory Board Economy-Wide Modeling Panel

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Environmental Protection Agency (EPA or Agency) Science
Advisory Board (SAB) Staff Office announces two public teleconferences
of the SAB Economy-Wide Modeling Panel. The SAB Staff Office also
announces a public face-to-face meeting of the SAB Economy-Wide
Modeling Panel.

DATES: The public teleconferences will be held on March 10, 2016 from 3
p.m. to 6 p.m. (Eastern Time) and May 19, 2016 from 1 p.m.-4 p.m.
(Eastern Time). The public face-to-face meeting will be held on July
19-20, 2016 from 9 a.m. to 5 p.m. each day (Eastern Time).

ADDRESSES: The teleconferences will be held by telephone only. The
face-to-face meeting will take place at George Washington University,
Milken Institute School of Public Health, Convening Center A and B, 950
New Hampshire Avenue NW., Washington, DC 20052. The public can view the
July 19-20, 2016 face-to-face meeting via a non-interactive, live
webcast that will be broadcast on the internet. The connection
information to view the webcast will be provided on the meeting Web
page at the time of the meeting. The meeting Web page may be found by
going to http://epa.gov/sab and clicking on the calendar then the
meeting date.

FOR FURTHER INFORMATION CONTACT: Any member of the public wishing
further information regarding the public teleconferences or public
meeting may contact Dr. Holly Stallworth, Designated Federal Officer
(DFO), SAB Staff Office, by telephone/voice mail at<PHONE_NUMBER> or
via email at<EMAIL_ADDRESS>General information concerning
the EPA Science Advisory Board can be found at the EPA SAB Web site at
http://epa.gov/sab.

SUPPLEMENTARY INFORMATION:
    Background: The SAB was established pursuant to the Environmental
Research, Development, and Demonstration Authorization Act (ERDAA)
codified at 42 U.S.C. 4365, to provide independent scientific and
technical peer review, advice, consultation, and recommendations to the
EPA Administrator on the technical basis for EPA actions. As a Federal
Advisory Committee, the SAB conducts business in accordance with the
Federal Advisory Committee Act (FACA) (5 U.S.C. App. 2) and related
regulations. Pursuant to FACA and EPA policy, notice is hereby given
that the SAB Economy-Wide Modeling Panel will hold two public
teleconferences to discuss its draft responses to charge questions from
EPA's National Center for Environmental Economics and the Office of Air
and Radiation on the role of economy-wide modeling in generating
estimates of social costs and benefits for air regulations at EPA.
After holding teleconferences on March 10, 2016 (3 p.m.-6 p.m.) and May
19, 2016 (1 p.m.-4 p.m.) to discuss its draft responses to charge
questions on social costs and benefits, the SAB Economy-Wide Modeling
Panel will hold a face-to-face meeting on July 19-20, 2016 to
deliberate on charge questions on analyzing economic impacts and
comparing estimates of social costs, benefits, and economic impacts
using economy-wide modeling. Some meeting time at the July 19-20, 2016
meeting may also be devoted to discussion of draft responses to EPA's
charge questions on social costs and benefits. The EPA-authored white
papers on economic impacts analysis and the comparison of estimates of
social costs, benefits and impacts using economy-wide modeling will be
provided to the Panel and the public prior to the July 19-20, 2016
face-to-face meeting. The SAB will comply with the provisions of FACA
and all appropriate SAB Staff Office procedural policies. Background
information on the SAB Economy-Wide Modeling Panel can be found at
http://yosemite.epa.gov/sab/sabproduct.nsf/fedrgstr_activites/Economywide%20modeling?OpenDocument.
    Availability of the meeting materials: Agendas, EPA's forthcoming
white papers and other meeting materials will be posted on the SAB Web
site prior to the teleconferences and face-to-face meeting. To find
these materials, go to http://epa.gov/sab and click on the calendar and
then the respective meeting dates. For questions concerning EPA's
review materials on economy-wide modeling, please contact Dr. Ann
Wolverton, EPA National Center for Environmental Economics at
<EMAIL_ADDRESS>or<PHONE_NUMBER>.
    Procedures for Providing Public Input: Public comment for
consideration by EPA's federal advisory committees and panels has a
different purpose from public comment provided to EPA program offices.
Therefore, the process for submitting comments to a federal advisory
committee is different from the process used to submit comments to an
EPA program office. Federal advisory committees and panels, including
scientific advisory committees, provide independent advice to the EPA.
Members of the public can submit relevant comments on the topic of this
advisory activity, including the charge to the Panel and the EPA review
documents, and/or the group conducting the activity, for the SAB to
consider during the advisory process. Input from the public to the SAB
will have the most impact if it consists of comments that provide
specific scientific or technical information or analysis for the SAB
panel to consider or if it relates to the clarity or accuracy of the
technical information.
    Oral Statements: In general, individuals or groups requesting an
oral presentation at the will be limited to five minutes per speaker
for the face-to-face meeting and three minutes per speaker for the
teleconference. Interested parties should contact Dr. Holly Stallworth,
DFO, in writing (preferably via email), at the contact information
noted above, one week (7 days) prior to the teleconference or face-to-
face meeting to be placed on the list of public speakers for that
teleconference or meeting.
    Written Statements: Written statements should be received in the
SAB Staff Office one week (7 days) prior to each meeting or
teleconference. Written statements should be supplied to the DFO,
preferably in electronic format via email. It is the SAB Staff Office
general policy to post written comments on the Web page for the
advisory meeting or teleconference. Submitters are requested to provide
an unsigned version of each document because the SAB Staff Office does
not publish documents with signatures on its Web sites. Members of the
public should be aware that their personal contact information, if
included in any written comments, may be posted to the SAB Web site.
Copyrighted material will not be posted without explicit permission of
the copyright holder.
    Accessibility: For information on access or services for
individuals with disabilities, please contact Dr. Stallworth at the
phone number or email address noted above, preferably at least ten days
prior to the meeting, to give EPA as much time as possible to process
your request.

    Dated: December 3, 2015.
Thomas H. Brennan,
 Deputy Director, EPA Science Advisory Board Staff Office.
[FR Doc. 2015-31465 Filed 12-14-15; 8:45 am]
 BILLING CODE 6560-50-P


PAPERWORK REDUCTION ACT SUBMISSION Please read the instructions before completing this form. For additional forms or assistance in completing this form, contact your agency's Paperwork Clearance Officer. Send two copies of this form, the collection instrument to be reviewed, the Supporting Statement and any additional documentation to: Office of Information and Regulatory Affairs, Office of Management and Budget, Docket Library, Room 10102, 725 17th Street NW Washington, DC 20503.

1. Agency/ Subagency originating request EPA\ Office of Enforcement and Compliance Assurance\ Office of Compliance 2. OMB control number b. G None a_ 2_ 0 6_ 0_  _ 0_ 1 2_ 2_ __ __ __ __ __ __

3. Type of information collection ( check one) a. G New collection b. G Revision of a currently approved collection c. X G Extension of a currently approved collection d. G Reinstatement, without change, of a previously approved collection for which approval has expired e. G Reinstatement, with change, of a previously approved collection for which approval has expired f. G Existing collection in use without an OMB control number 4. Type of review requested ( check one) a. X G Regular b. G Emergency  Approval requested by: / / c. G Delegated 5. Small entities Will this information collection have a significant economic impact on a substantial number of small entities? G Yes X G No For b f, note item A2 of Supporting Statement Instructions 6. Requested expiration date a. X G Three years from approval date b. G Other Specify: / /___

7. Title NSPS for Coal Preparation Plants  Subpart Y 8. Agency form number( s) ( If applicable) ICR# 1062.07 9. Keywords Coal preparation, particulate matter, opacity 10. Abstract This standard requires owners and operators of coal preparation plants to keep records and make reports to the Administrator. The records and reports enable the Administrator to determine the best demonstrated control technology is installed and properly operated and maintained.

11. Affected public ( Mark primary with " P" and all others that apply with " X") a. Individuals or households d. Farms b. X Business or other for profit e. Federal Government c. Not for profit institutions f. State, Local or Tribal Government 12. Obligation to respond ( Mark primary with " P" and all others that apply with " X") a. G Voluntary b. G Required to obtain or retain benefits c. PG Mandatory 13. Annual reporting and recordkeeping hour burden a. Number of respondents 390 b. Total annual responses 390 1. Percentage of these responses collected electronically 0 % c. Total hours requested 15463 d. Current OMB inventory 18729 e. Difference  3266 f. Explanation of difference 1. Program Change 0 2. Adjustment  3266 14. Annual reporting and recordkeeping cost burden ( in thousands of dollars)

a. Total annualized capital/ startup costs $ 1 b. Total annual costs ( O& M) $ 14 c. Total annualized cost requested $ 15 d. Current OMB inventory $ 14 e. Difference $ 1 f. Explanation of difference 1. Program change $ 0 2. Adjustment $ 1 15. Purpose of information collection ( Mark Primary With " P" and all others that apply with " X") a. __ Application for benefits e. __ Program planning or management b. __ Program evaluation f. __ Research c. __ General purpose statistics g. _ P_ Regulatory or compliance d. __ Audit 16. Frequency of recordkeeping or reporting ( check all that apply) a. X Q Recordkeeping b. Q Third party disclosure c. X Q Reporting 1. X On occasion 2. Q Weekly 3. Q Monthly 4. Q Quarterly 5. Q Semi annually 6. Q Annually 7. Q Biannually 8. Q Other ( describe) 17. Statistical methods Does this information collection employ statistical methods?

Q Yes X Q No 18. Agency contact ( person who can best answer questions regarding the content of this submission) Name: Dan Chadwick Phone: ( 202) 564 7054 OMB 83 I 10/ 95


[Federal Register: June 8, 2009 (Volume 74, Number 108)]
[Notices]
[Page 27146-27148]
[DOCID:fr08jn09-56]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-D-0369] (formerly Docket No. 2007D-0169)

Draft and Revised Draft Guidances for Industry Describing
Product-Specific Bioequivalence Recommendations; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of additional draft and revised draft product-specific
bioequivalence (BE) recommendations. The recommendations provide
product-specific guidance on the design of BE studies to support
abbreviated new drug applications (ANDAs). In the Federal Register of
May 31, 2007, FDA announced the availability of a draft guidance for
industry entitled ``Bioequivalence Recommendations for Specific
Products'' explaining the process that would be used to make product-
specific BE recommendations available to the public on FDA's Web site.
The BE recommendations identified in this notice were developed using
the process described in that guidance. Elsewhere in this issue of the
Federal Register, FDA is announcing the availability of final product-
specific BE recommendations.

DATES: Submit written or electronic comments on the draft and revised
draft product-specific BE recommendations listed in this notice by
September 8, 2009.

ADDRESSES: Submit written requests for single copies of the individual
BE guidances to the Division of Drug Information, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your requests. Submit written comments on the draft product-specific BE
recommendations to the Division of Dockets Management (HFA-305), Food
and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD
20852. Submit electronic comments to http://www.regulations.gov. See
the SUPPLEMENTARY INFORMATION section for electronic access to the
recommendations.

FOR FURTHER INFORMATION CONTACT:  Doan T. Nguyen, Center for Drug
Evaluation and Research (HFD-600), Food and Drug Administration, 7519
Standish Pl., Rockville, MD 20855,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    In the Federal Register of May 31, 2007 (72 FR 30388), FDA
announced the availability of a draft guidance for industry entitled
``Bioequivalence Recommendations for Specific Products'' that explained
the process that would be used to make product-specific BE
recommendations available to the public on FDA's Web site at http://
www.fda.gov/cder/guidance/bioequivalence/default.htm. As described in
that draft guidance, FDA adopted this process as a means to develop and
disseminate product-specific BE recommendations and provide a
meaningful opportunity for

the public to consider and comment on those recommendations. Under that
process, draft recommendations are posted on FDA's Web site and
announced periodically in the Federal Register. The public is
encouraged to submit comments on those recommendations within 90 days
of their announcement in the Federal Register. FDA considers any
comments received and either publishes final recommendations, or
publishes revised draft recommendations for comment. Recommendations
were last announced in the Federal Register of September 5, 2008 (73 FR
51829). This notice announces draft product-specific recommendations,
either new or revised, that have been posted on FDA's Web site in the
period from May 1, 2008, through October 31, 2008. Final product-
specific recommendations are being announced elsewhere in this issue of
the Federal Register.

II. Drug Products for Which Draft Product-Specific BE Recommendations
Are Available

    FDA is announcing draft BE product-specific recommendations for
drug products containing the following active ingredients:

A
Acetazolamide
Adefovir Dipivoxil
Albuterol Sulfate
Aliskiren Hemifumarate
Alprazolam
Aminosalicylic Acid
Amlodipine Besylate; Olmesartan Medoxomil
Amlodipine Besylate; Valsartan
Amprenavir
Atovaquone; Proguanil
Azacitidine
Azithromycin

B
Baclofen
Bethanechol Chloride
Bismuth Subcitrate Potassium; Metronidazole; Tetracycline HCl
Brimonidine Tartrate
Bumetanide
Busulfan

C
Calcitriol
Capecitabine
Citalopram HBr (multiple dosage forms)
Clotrimazole
Colesevelam HCl
Cyclobenzaprine HCl

D
Demeclocycline HCl
Desogestrel; Ethinyl Estradiol
Diflunisal
Disopyramide Phosphate (multiple dosage forms)
Doxercalciferol
Doxycycline
Doxycycline Hyclate

E
Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate
Enalapril Maleate
Eprosartan Mesylate
Escitalopram Oxalate
Ethinyl Estradiol; Levonorgestrel
Ethinyl Estradiol; Norethindrone Acetate (multiple reference listed
drugs (RLDs))
Ethosuximide
Ezetimibe; Simvastatin
Ezetimibe

F
Famciclovir
Fenofibrate (multiple dosage forms)
Fexofenadine HCl
Frovatriptan Succinate

G
Gatifloxacin
Glipizide
Goserelin Acetate
Griseofulvin, Ultramicrocrystalline

H
Hydrochlorothiazide; Telmisartan
Hydrochlorothiazide; Triamterene
Hydralazine HCl
Hydroxyurea

I
Ibuprofen (multiple dosage forms)
Indapamide
Isoniazid
Isotretinoin

K
Ketoconazole
Ketorolac Tromethamine

L
Lansoprazole
Latanoprost
Letrozole
Leucovorin Calcium
Leuprolide Acetate
Levocetirizine Dihydrochloride
Levofloxacin
Lisdexamfetamine Dimesylate
Lithium Carbonate
Lopinavir; Ritonavir
Loratadine

M
Mebendazole
Melphalan
Metformin HCl
Methadone HCl
Midodrine HCl
Minocycline HCl
Montelukast
Montelukast Sodium
Moxifloxacin HCl

N
Nabilone
Naltrexone HCl
Naproxen Sodium (multiple RLDs)
Naratriptan HCl
Nicardipine HCl

O
Olanzapine
Olopatadine HCl
Omeprazole; Sodium Bicarbonate

P
Paroxetine HCl
Penicillamine
Phenoxybenzamine HCl
Prednisolone Sodium Phosphate

Q
Quetiapine Fumarate

R
Ramipril
Repaglinide

S
Sapropterin Dihydrochloride
Selegiline HCl
Sevelamer Carbonate
Sevelamer HCl
Simvastatin
Sitagliptin Phosphate; Metformin HCl
Sodium Iodide
Stavudine
Sulfadiazine
Sulfamethoxazole; Trimethoprim

T
Theophylline
Tiagabine HCl
Triptorelin Pamoate
Trospium Cl

U
Ursodiol

V
Valganciclovir HCl
Verapamil HCl
Vorinostat

Z
Zileuton
Ziprasidone HCl

III. Drug Products for Which Revised Draft Product-Specific BE
Recommendations Are Available

    FDA is announcing revised draft BE product-specific recommendations
for drug products containing the following active ingredients. These
recommendations were previously posted on FDA's Web site.

A
Alprazolam

C
Candesartan Cilexetil; Hydrochlorothiazide
Carbidopa; Entacapone; Levodopa
Clopidogrel Bisulfate

F
Fexofenadine HCl (multiple dosage forms)
Fosinopril Sodium; Hydrochlorothiazide

H
Hydrochlorothiazide; Valsartan

M
Minoxidil
Montelukast Sodium
Morphine Sulfate

S
Sirolimus

Z
Zolmitriptan
    For a complete history of previously published Federal Register
notices, please go to http://www.regulations.gov and enter docket
number FDA-2007-D-0369.
    These guidances are being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The guidances represent
the agency's current thinking on product-specific design of BE studies
to support ANDAs. They do not create or confer any rights for or on any
person and do not operate to bind FDA or the public. An alternative
approach may be used if such approach satisfies the requirements of the
applicable statutes and regulations.

IV. Comments

    Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments on any of the specific
BE recommendations posted on FDA's Web site. Submit a single copy of
electronic comments or two paper copies of any mailed comments, except
that individuals may submit one paper copy. Comments are to be
identified with the docket number found in brackets in the heading of
this document. The guidance, notices, and received comments may be seen
in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.

V. Electronic Access

    Persons with access to the Internet may obtain the document at
either http://www.fda.gov/cder/guidance/index.htm or http://
www.regulations.gov.

    Dated: May 27, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-13272 Filed 6-5-09; 8:45 am]

BILLING CODE 4160-01-S


P-19-0121 Sanitized Support Documents Index:
 P-19-0121 Sanitized Determination Document (linked)
 P-19-0121 Sanitized CHEM Report (attached)
 P-19-0121 Sanitized ECO Report (attached)
 P-19-0121 Sanitized ENG Report (attached)
 P-19-0121 Sanitized EXP Report (attached)
 P-19-0121 Sanitized Fate Report (attached)
 P-19-0121 Sanitized HLTH Report_POST-FOCUS FINAL (attached)


[Federal Register Volume 78, Number 83 (Tuesday, April 30, 2013)]
[Notices]
[Pages 25289-25290]
[FR Doc No: 2013-10131]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA-2008-0010]

Board of Visitors for the National Fire Academy Teleconference

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Committee Management; Notice of Open Federal Advisory Committee
Teleconference.

-----------------------------------------------------------------------

SUMMARY: The Board of Visitors for the National Fire Academy (Board)
will meet via teleconference on Wednesday, May 15, 2013. The meeting
will be open to the public.

DATE:  The Board of Visitors for the National Fire Academy will meet on
Wednesday, May 15, 2013, from 1:30 to 4:00 p.m. Eastern Daylight Time.
Please note that the meeting may close early if the Board has completed
its business.

ADDRESSES: Members of the public who wish to participate in the
teleconference should contact Cindy Wivell as listed below in the FOR
FURTHER INFORMATION CONTACT section by close of business May 8, 2013,
to obtain the call-in number and access code. For information on
services for individuals with disabilities or to request special
assistance, contact Cindy Wivell as soon as possible.
    To facilitate public participation, we are inviting public comment
on the issues to be considered by the Board as listed below in the
SUPPLEMENTARY INFORMATION section. Comments must be submitted in
writing no later than May 8, 2013, and must be identified by docket ID
FEMA-2008-0010 and may be submitted by one of the following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments.
     Mail/Hand Delivery: Cindy Wivell, 16825 South Seton
Avenue, Emmitsburg, Maryland 21727.
    Instructions: All submissions received must include the words
``Department of Homeland Security'' and the docket ID for this action.
Comments received will be posted without alteration at http://www.regulations.gov, including any personal information provided.
    Docket: For access to the docket to read background documents or
comments received by the National Fire Academy Board of Visitors, go to
http://www.regulations.gov. The documents will be posted on http://www.regulations.gov as soon as they are available.
    There will be a 6-minute comment period after each agenda item;
each speaker will be given no more than 2 minutes to speak. Please note
that the public comment period may end before the time indicated,
following the last call for comments. Contact Cindy Wivell to register
as a speaker.

FOR FURTHER INFORMATION CONTACT:
    Alternate Designated Federal Officer: Denis G. Onieal, telephone
(301) 447-1117.
    Logistical Information: Cindy Wivell, telephone<PHONE_NUMBER>, fax
(301) 447-1834, and email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the
Federal Advisory Committee Act, 5 U.S.C. App. (Pub. L. 92-463).

Purpose of the Board

    The purpose of the Board is to review annually the programs of the
National Fire Academy (Academy) and advise the Administrator of the
Federal Emergency Management Agency (FEMA), through the United States
Fire Administrator, of the operation of the Academy and any
improvements therein that the Board deems appropriate. The Board makes
interim advisories to the Administrator of FEMA, through the United
States Fire Administrator, whenever there is an indicated urgency to do
so in fulfilling its duties. In carrying out its responsibilities, the
Board examines Academy programs to determine whether these programs
further the basic missions which are approved by the Administrator of
FEMA, examines the physical plant of the Academy to determine the
adequacy of the Academy's facilities, and examines the funding levels
for Academy programs. The Board submits an annual report through the
United States Fire Administrator to the Administrator of FEMA, in
writing. The report provides detailed comments and recommendations
regarding the operation of the Academy.

Agenda

    The Board will review and approve the minutes of the December 5,
2012, teleconference meeting. The Board will discuss deferred
maintenance and capital improvements on the National Emergency Training
Center (NETC) campus, to include FY 2013 Budget Planning. The Board
will receive a status report on U.S. Fire Administration data, research
and response support initiatives. The Board

will review and give feedback on Academy program activities including
Executive Fire Officer Program (EFOP) prerequisites/accreditation
update, FY 2013 curriculum developments update, EFOP Symposium,
transition to electronic student manuals, and follow up to state
training system/semi-annual course call.
    The Board will discuss the Fire and Emergency Services Higher
Education (FESHE)/Professional Development Subcommittee activities,
including the FESHE committee's realignment, National Professional
Development Symposium, and FESHE Recognition Update.
    The Board will discuss dates and agenda items for upcoming meetings
and the logistics for completing the 2012 BOV NFA annual report.
    The public will have an opportunity to comment on these issues
prior to deliberation and final action by the Board. After
deliberation, the Board will recommend actions to the Superintendent of
the National Fire Academy and the Administrator of FEMA.

    Dated: April 25, 2013.
Denis G. Onieal,
Superintendent, National Fire Academy, United States Fire
Administration, Federal Emergency Management Agency.
[FR Doc. 2013-10131 Filed 4-29-13; 8:45 am]
BILLING CODE 9111-45-P


[Federal Register Volume 79, Number 6 (Thursday, January 9, 2014)]
[Notices]
[Pages 1643-1644]
[FR Doc No: 2014-00156]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY, REGION 9

[FRL-9905-23-Region 9]

Reissuance of National Pollutant Discharge Elimination System
(NPDES) General Permit for Offshore Oil and Gas Exploration,
Development and Production Operations Off Southern California

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of availability of final NPDES general permit.

-----------------------------------------------------------------------

SUMMARY: EPA Region 9 is today publishing this notice of availability
of its final general NPDES permit (permit No. CAG280000) for discharges
from offshore oil and gas exploration, development and production
facilities located in Federal waters off the coast of Southern
California. The general permit establishes effluent limitations,
prohibitions, and other conditions for discharges from facilities that
engage in such operations within the geographic coverage area of the
general permit. The general permit applies to 23 existing development
and production platforms as well as to any new exploratory drilling
operations located in and discharging to the specified lease blocks on
the Pacific Outer Continental Shelf covered by the permit. The new
general permit replaces the previous general permit issued on September
22, 2004 (69 FR 56761).

DATES: For purposes of judicial review the permit is considered issued
on January 23, 2014. The final permit was signed on December 20, 2013
and is effective on March 1, 2014.

ADDRESSES: The final general permit and other related documents in the
administrative record are on file and may be inspected any time between
8:30 a.m. and 4:00 p.m., Monday through Friday, excluding legal
holidays, at the following address: U.S. EPA, Region 9, NPDES Permits
Office (WTR-5), 75 Hawthorne Street, San Francisco, CA 94105-3901.

FOR FURTHER INFORMATION CONTACT: Eugene Bromley, EPA, Region 9, NPDES
Permits Office (WTR-5), 75 Hawthorne Street, San Francisco, California
94105-3901, or telephone<PHONE_NUMBER>. Copies of the final general
permit, Addendum to Fact Sheet and the Response to Public Comments will
be provided upon request and are also available at EPA, Region 9's Web
site at: http://www.epa.gov/region9/water/npdes/permits.html.

SUPPLEMENTARY INFORMATION: Public notice of Region 9's tentative
decision to issue the permit was published in the Federal Register on
December 20, 2012 (77 FR 75429), and in the Santa Barbara News-Press on
December 19, 2012. The public comment period closed on February 4,
2013. Region 9 received written comments from eight parties concerning
the proposed permit. Region 9 prepared a separate document (Response to
Public Comments) which discusses these comments in more detail and
Region 9's responses to the comments.
    For the most part, the final permit is very similar to the permit
proposed in December 2012. However, the monitoring requirements for
produced water discharges were revised based on public comments and
also discussions between Region 9 and California Coastal Commission
(CCC) staff concerning Region 9's consistency determination for the
permit pursuant to the Coastal Zone Management Act (CZMA). Region 9
also added a requirement to maintain an inventory of the chemicals used
to formulate well treatment, completion and workover fluids, and if
there is a discharge of the fluids, to report the chemical formulation
with the quarterly discharge monitoring report. This requirement was
added in response to recent concerns regarding the potential effects of
discharges of fluids used for offshore hydraulic fracturing operations.
    The final permit also includes a number of technical corrections
and other relatively minor revisions based on public comment or other
sources. These revisions are discussed in more detail in the Response
to Public Comments and the final Addendum to Fact Sheet.

    B. Endangered Species Act (ESA). The ESA and its implementing
regulations (50 CFR Part 402) require EPA to ensure, in consultation
with the Secretary of the Interior or Commerce, that any action
authorized, funded or carried out by EPA is not likely to jeopardize
the continued existence of any threatened or endangered species or
adversely affect its critical habitat.
    For the 2004 permit, Region 9 concluded that the authorized
discharges would not affect listed species or critical habitat for the
species. For the general permit reissuance, Region 9 reconsidered this
matter, but again concluded that the discharges would not affect such
species. Region 9 also forwarded the draft permit and fact sheet to the
U.S. Fish and Wildlife Service (USFWS) and the National Marine
Fisheries Service (NMFS) for review and comment on Region 9's
conclusion, but no comments were received.
    C. Coastal Zone Management Act (CZMA). The CZMA provides that a
Federal license or permit for activities affecting the coastal zone of
a state may not be granted until a state with an approved Coastal
Management Plan (CMP) concurs that the activities authorized by the
permit are consistent with the CMP. In California, the CZMA authority
is the CCC.
    In accordance with the requirements of the CZMA and its
implementing regulations at 15 CFR Part 930, Region 9 submitted a
consistency determination for the draft permit to the CCC in a letter
dated December 20, 2012. Region 9 and CCC staff also met in spring 2013
to discuss the permit and conditions necessary to ensure consistency
with the CMP. Based on those discussions, Region 9 submitted an amended
consistency determination in a letter dated May 2, 2013. At a public
meeting held on June 12, 2013, the CCC concurred with Region 9's
consistency determination.
    D.  Magnuson-Stevens Fishery Conservation and Management Act. The
1996 amendments to the Magnuson-Stevens Fishery Conservation and
Management Act set forth a number of new mandates for NMFS, regional
fishery management councils, and Federal agencies to identify and
protect important marine and anadromous fish habitat. Regional fishery
management councils, with assistance from NMFS, are required to
delineate essential fish habitat (EFH).
    The Magnuson-Stevens Act requires that Federal agencies consult
with NMFS on all actions undertaken by the agency which may adversely
affect EFH. For the 2004 general permit, EPA concluded that the
discharges would not have a significant adverse effect on EFH. After a
consultation was held regarding the 2004 permit, NMFS concurred with
Region 9's conclusion.
    For the general permit reissuance, Region 9 reconsidered the
effects of the discharges on EFH, but again concluded that the
discharges would not have a significant adverse effect on EFH. The
draft permit and fact sheet were forwarded to NMFS for review and
comment on Region 9's conclusion, but no comments were received.
    E. Permit Appeal Procedures. Within 120 days following the date the
permit is considered issued for purposes of judicial review, any
interested person may appeal the permit decision in the Federal Court
of Appeals in accordance with Section 509(b)(1) of the CWA. Persons
affected by a general permit may not challenge the conditions of a
general permit as a right in further Agency proceedings. They may
instead either challenge the general permit in court, or apply for an
individual permit as specified at 40 CFR 122.21 (and authorized at 40
CFR 122.28), and then petition the Environmental Appeals Board to
review any condition of the individual permit (40 CFR 124.19).
    F. Regulatory Flexibility Act. The Regulatory Flexibility Act, 5
U.S.C. 601 et seq, requires that EPA prepare a regulatory flexibility
analysis for regulations that have a significant impact on a
substantial number of small entities. The permit issued today is not a
``rule'' subject to the Regulatory Flexibility Act. EPA prepared a
regulatory flexibility analysis, however, on the promulgation of the
Offshore Subcategory guidelines on which many of the permit's effluent
limitations are based. That analysis has shown that issuance of this
permit would not have a significant impact on a substantial number of
small entities.
    G. Paperwork Reduction Act. The information collection required by
this final permit has been approved by Office of Management and Budget
(OMB) under the provisions of the Paperwork Reduction Act, 44 U.S.C.
3501 et. seq., in submissions made for the NPDES permit program and
assigned OMB control numbers 2040-0086 (NPDES permit application) and
2040-0004 (discharge monitoring reports).

    Authority: Clean Water Act, 33 U.S.C. 1251 et seq.

    Dated: December 20, 2013.
Jane Diamond,
Director, Water Division, EPA Region 9.
[FR Doc. 2014-00156 Filed 1-8-14; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 84, Number 140 (Monday, July 22, 2019)]
[Notices]
[Pages 35143-35144]
[FR Doc No: 2019-15529]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[SEC File No. 270-93, OMB Control No. 3235-0087]

Proposed Collection; Comment Request

Upon Written Request, Copies Available From: Securities and Exchange
Commission, Office of FOIA Services, 100 F Street NE, Washington, DC
20549-2736.

Extension:
    Rule 15Bc3-1 and Form MDSW--Withdrawal from Registration of
Municipal Securities Dealers.

    Notice is hereby given that, pursuant to the Paperwork Reduction
Act of 1995 (``PRA'') (44 U.S.C. 3501 et seq.), the Securities and
Exchange Commission (``Commission'') is soliciting comments on the
existing collection of information provided for in Rule 15Bc3-1 (17 CFR
15Bc3-1) and Form MSDW (17 CFR 249.1110) under the Securities Exchange
Act of 1934 (15 U.S.C. 78a et seq.). The Commission plans to submit
this existing collection of information to the Office of Management and
Budget (``OMB'') for extension and approval.
    Rule 15Bc3-1 provides that a notice of withdrawal from registration
with the Commission as a bank municipal securities dealer must be filed
on Form MSDW. The Commission uses the information submitted on Form
MSDW in determining whether it is in the public interest to permit a
bank municipal securities dealer to withdraw its registration. This
information is also important to the municipal securities dealer's
customers and to the public, because it provides, among other things,
the name and address of a person to contact regarding any of the
municipal securities dealer's unfinished business.
    Based upon past submissions of one filing in 2016, two filings in
2017, zero filings in 2018, and one filing so far in 2019, the staff
estimates that, on an annual basis, approximately one bank municipal
securities dealer will file a notice of withdrawal from registration
with the Commission as a bank municipal securities dealer on Form MSDW.
The staff estimates that the average number of hours necessary to
comply with the notice requirements set out in Rule 15Bc3-1 and Form
MSDW is 0.5 per respondent, for a total burden of 0.5 hours per year.
The staff estimates that the average internal compliance cost per hour
is approximately $417.\1\ Therefore, the estimated total annual cost of
compliance is approximately $209 per year (0.5 hours/year x $417/hour =
$208.5/year, rounded up to $209).
---------------------------------------------------------------------------

    \1\ The estimate of $417 per hour is for a compliance attorney,
based on the Securities Industry and Financial Markets Association's
Management & Professional Earnings in the Securities Industry 2013,
modified by Commission staff to account for an 1800-hour work-year
and inflation, and multiplied by 5.35 to account for bonuses, firm
size, employee benefits and overhead.
---------------------------------------------------------------------------

    Rule 15Bc3-1 does not contain an explicit recordkeeping
requirement, but the instructions for filing Form MSDW state that an
exact copy should be retained by the registrant. Providing the
information on the application is

mandatory in order to withdraw from registration with the Commission as
a bank municipal securities dealer. The information contained in the
notice will not be kept confidential.
    Written comments are invited on: (a) Whether the proposed
collection of information is necessary for the proper performance of
the functions of the Commission, including whether the information will
have practical utility; (b) the accuracy of the Commission's estimate
of the burden of the collection of information; (c) ways to enhance the
quality, utility, and clarity of the information to be collected; and
(d) ways to minimize the burden of the collection of information on
respondents, including through the use of automated collection
techniques or other forms of information technology. Consideration will
be given to comments and suggestions submitted in writing within 60
days of this publication.
    An agency may not conduct or sponsor, and a person is not required
to respond to, a collection of information subject to the PRA unless it
displays a currently valid OMB control number.
    Please direct your written comments to: Charles Riddle, Acting
Director/Chief Information Officer, Securities and Exchange Commission,
c/o Candace Kenner, 100 F Street NE, Washington, DC 20549, or send an
email to<EMAIL_ADDRESS>
    Dated: July 17, 2019.
Jill M. Peterson,
Assistant Secretary.
[FR Doc. 2019-15529 Filed 7-19-19; 8:45 am]
 BILLING CODE 8011-01-P